Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The small size of this peptide enables it to enter cells and cell nuclei where it has been shown to induce and stabilize DNA telomere lengthening and thereby prolong the duration of cell survival in vitro
It does not interact with cytochrome P450 enzymes in the liver, which means fewer drug interaction concerns than many other medications
C.RanadheeraC
BPC-157 is active treatment
Certain chemotherapy regimens, some antibiotics if taken for long periods, and long-term use of the epilepsy drug phenytoin, carry a risk of nerve damage
Eli Lilly developed the peptide as the next step beyond dual incretin agonists such as tirzepatide, and researchers now study it across obesity, type 2 diabetes and metabolic liver disease
US$ 27.77
US$ 26.96
US$ 24.80
US$ 28.87
US$ 21.00
US$ 23.43
